title: Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Yanaba
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Umezawa
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Hiromi
authors.initials: H
authors.lastname: Honda
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Reiko
authors.initials: R
authors.lastname: Sato
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Miki
authors.initials: M
authors.lastname: Chiba
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Sota
authors.initials: S
authors.lastname: Kikuchi
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Asahina
authors.affiliation: Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Hidemi
authors.initials: H
authors.lastname: Nakagawa
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000974:Antibodies, Antinuclear / Q000097:blood / Q000187:drug effects* / Q000276:immunology; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D007564:Japan; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab